Advertisement

Oral Manifestations of Systemic Diseases and their Treatments

  • Sue-Ching Yeoh
  • Hong Hua
  • Juan Fernando Yepes
  • Douglas E. Peterson
Living reference work entry

Abstract

The oral cavity can be affected by a wide range of systemic diseases, as well as systemic treatments for those diseases. Types of disorders include cardiovascular disease, gastrointestinal disease, endocrinopathies, hematologic disease, cancer, obesity, osteoporosis, and neurologic disease. Oral lesions caused by treatment of systemic diseases can also be clinically significant, including those caused by cancer therapies and as well as medications that result in salivary compromise.

This chapter will address the impact of key selected systemic diseases and/or systemic treatment on oral tissues. While the majority of such adverse effects on the oral cavity involve the oral mucosa, selected disorders can affect the dentition, periodontium, and/or salivary gland structures as well.

Keywords

Oral cavity Oral manifestations Systemic disease Systemic treatment Treatment effects Dental considerations Medication-induced oral abnormalities 

References

  1. Abdollahi M, Rahimi R, Radfar M. Current opinion on drug-induced oral reactions: a comprehensive review. J Contemp Dent Pract. 2008;9(3):1–15.PubMedGoogle Scholar
  2. ABIM Foundation. Choosing wisely. 2018. Retrieved 14 Jan 2018.Google Scholar
  3. Acharya SS, Rule B, McMillan O, Humphries TJ. Point-of-care ultrasonography (POCUS) in hemophilia a: a commentary on current status and its potential role for improving prophylaxis management in severe hemophilia a. Ther Adv Hematol. 2017;8(4):153–6.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.PubMedCrossRefGoogle Scholar
  5. Aine L. Dental enamel defects and dental maturity in children and adolescents with coeliac disease. Proc Finn Dent Soc. 1986;82(Suppl 3):1–71.PubMedGoogle Scholar
  6. Aine L, Mäki M, Collin P, Keyriläinen O. Dental enamel defects in celiac disease. J Oral Pathol Med. 1990;19(6):241–5.PubMedCrossRefGoogle Scholar
  7. Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E. Relationship between periodontal findings and Behcet's disease: a controlled study. J Clin Periodontol. 2007;34(6):485–91.PubMedCrossRefGoogle Scholar
  8. Akman A, Sallakci N, Kacaroglu H, Tosun O, Yavuzer U, Alpsoy E, Yegin O. Relationship between periodontal findings and the TNF-alpha gene 1031T/C polymorphism in Turkish patients with Behcet's disease. J Eur Acad Dermatol Venereol. 2008;22(8):950–7.PubMedCrossRefGoogle Scholar
  9. Al-Araji A, Kidd DP. Neuro-Behcet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.PubMedCrossRefGoogle Scholar
  10. Alawi F. Pigmented lesions of the oral cavity: an update. Dent Clin N Am. 2013;57(4):699–710.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Al-Otaibi LM, Porter SR, Poate TW. Behcet's disease: a review. J Dent Res. 2005;84(3):209–22.PubMedCrossRefGoogle Scholar
  12. Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2010;51(3):376–89.PubMedCrossRefGoogle Scholar
  13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.[erratum appears in J am Coll Cardiol 2001 mar 1;37(3):973]. J Am Coll Cardiol. 2000;36(3):959–69.PubMedCrossRefGoogle Scholar
  14. Alpsoy E. Behcet's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol. 2005;23(4):532–9.PubMedGoogle Scholar
  15. Alpsoy E. New evidence-based treatment approach in Behcet's disease. Patholog Res Int. 2012;2012:871019.PubMedGoogle Scholar
  16. Alpsoy E. Behcet's disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620–32.PubMedCrossRefGoogle Scholar
  17. Alpsoy E, Akman A. Treatment of Behcet's disease. Therapy. 2006;3:139–51.Google Scholar
  18. Alpsoy E, Akman A. Behcet's disease: an algorithmic approach to its treatment. Arch Dermatol Res. 2009;301(10):693–702.PubMedCrossRefGoogle Scholar
  19. Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E. A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet's patients. Int J Dermatol. 1998;37(11):839–42.PubMedCrossRefGoogle Scholar
  20. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–71.PubMedCrossRefGoogle Scholar
  21. Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet's disease. Yonsei Med J. 2007;48(4):573–85.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Al-Waiz MM, Sharquie KE, MH AQ, Hayani RK. Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J. 2005;11(3):3.PubMedGoogle Scholar
  23. Amagai M. Pemphigus: autoimmunity to epidermal cell adhesion molecules. Adv Dermatol. 1996;11:319–52.Google Scholar
  24. Amagai M. Pemphigus as a paradigm of autoimmunity and cell adhesion. Keio J Med. 2002;51(3):133–9.PubMedCrossRefGoogle Scholar
  25. American Cancer Society. American Cancer Society. Cancer facts & figures 2017. 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
  26. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology ad hoc Committee on systemic lupus Erythematosus guidelines. Arthritis Rheum. 1999;42(9):1785–96.CrossRefGoogle Scholar
  27. American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology. 2003;125(5):1503–7.CrossRefGoogle Scholar
  28. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–17.PubMedCrossRefGoogle Scholar
  29. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104(5):1565–73.PubMedCrossRefGoogle Scholar
  30. Andres E, Mourot-Cottet R. Non-chemotherapy drug-induced neutropenia - an update. Expert Opin Drug Saf. 2017;16(11):1235–42.PubMedCrossRefGoogle Scholar
  31. Andres E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Severac F, Tebacher M, Gottenberg JE, Weber JC, Kaltenbach G, Goichot B, Sibilia J, Korganow AS, Herbrecht R. History and outcome of febrile neutropenia outside the oncology setting: a retrospective study of 76 cases related to non-chemotherapy drugs. J Clin Med. 2017;6(10):92.  https://doi.org/10.3390/jcm6100092PubMedCentralCrossRefPubMedGoogle Scholar
  32. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64.PubMedCrossRefGoogle Scholar
  33. Aono J, Mamiya K, Ueda W. Abrupt onset of adrenal crisis during routine preoperative examination in a patient with unknown Addison's disease. Anesthesiology. 1999;90(1):313–4.PubMedCrossRefGoogle Scholar
  34. Aoyama Y, Nagasawa C, Nagai M, Kitajima Y. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG. Eur J Dermatol. 2008;18(5):557–60.PubMedGoogle Scholar
  35. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol. 1998;134(5):602–12.PubMedCrossRefGoogle Scholar
  36. Aragon CE, Burneo JG. Understanding the patient with epilepsy and seizures in the dental practice. J Can Dent Assoc. 2007;73(1):71–6.PubMedGoogle Scholar
  37. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.PubMedCrossRefGoogle Scholar
  38. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620–5.PubMedCrossRefGoogle Scholar
  39. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361(9372):1881–93.PubMedCrossRefGoogle Scholar
  40. Armstrong MJ, Gronseth G, Anderson DC, Biller J, Cucchiara B, Dafer R, Goldstein LB, Schneck M, Messe SR. Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the guideline development Subcommittee of the American Academy of neurology. Neurology. 2013;80(22):2065–9.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood. 2017;130(21):2251–6.PubMedCrossRefGoogle Scholar
  42. Aubertin MA. The hypertensive patient in dental practice: updated recommendations for classification, prevention, monitoring, and dental management. Gen Dent. 2004;52(6):544–52. quiz 553, 527–548PubMedGoogle Scholar
  43. Aydemir S, Tekin NS, Aktunc E, Numanoglu G, Ustundag Y. Celiac disease in patients having recurrent aphthous stomatitis. Turk J Gastroenterol. 2004;15(3):192–5.PubMedGoogle Scholar
  44. Azizlerli G, Kose AA, Sarica R, Gul A, Tutkun IT, Kulac M, Tunc R, Urgancioglu M, Disci R. Prevalence of Behcet's disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–6.PubMedCrossRefGoogle Scholar
  45. Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M, Cristea V, Douet-Guilbert N, Renaudineau Y. Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion. Clin Epigenetics. 2017;9:122.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Bagan J, Lo Muzio L, Scully C. Mucosal disease series. Number III. Mucous membrane pemphigoid. Oral Dis. 2005;11(4):197–218.PubMedCrossRefGoogle Scholar
  47. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in ambulatory oral anticoagulant use. Am J Med. 2015;128(12):1300–5. e1302PubMedPubMedCentralCrossRefGoogle Scholar
  48. Barnett ML. Pemphigus vulgaris presenting as a gingival lesion. A case report. J Periodontol. 1988;59(9):611–4.PubMedCrossRefGoogle Scholar
  49. Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. Journal of the European Academy of Dermatology & Venereology. 2006;20(5):548–52.CrossRefGoogle Scholar
  50. Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev. 2014:13(4–5):482–9.  https://doi.org/10.1016/j.autrev.2014.01.047. Epub 2014 Jan 13.PubMedCrossRefGoogle Scholar
  51. Bavitz JB. Dental management of patients with hypertension. Dent Clin N Am. 2006;50(4):547–62.PubMedCrossRefGoogle Scholar
  52. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. the Framingham heart study. JAMA. 1994;271(11):840–4.PubMedCrossRefGoogle Scholar
  53. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res. 2000;79(9):1652–8.PubMedCrossRefGoogle Scholar
  54. Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, Lorette G, Bonnetblanc JM, Prost C. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous diseases French study group. Arch Dermatol. 1995;131(1):48–52.PubMedCrossRefGoogle Scholar
  55. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–7.PubMedCrossRefGoogle Scholar
  56. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis. 2004;74(4):245–7.PubMedGoogle Scholar
  57. Bertram F, Brocker E-B, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–40.PubMedGoogle Scholar
  58. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195–205.PubMedCrossRefGoogle Scholar
  59. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–82.PubMedCrossRefGoogle Scholar
  60. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dorner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT. Joint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology. 1994;189(Suppl 1):85–9.PubMedCrossRefGoogle Scholar
  62. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.PubMedGoogle Scholar
  63. Binnie WH, Curro FA, Khandwala A, Van Inwegan RG. Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent. 1997;18(11):1116–8, 1120–1112, 1124 passimPubMedGoogle Scholar
  64. Black M, Mignogna MD, Scully C. Number II. Pemphigus vulgaris. Oral Dis. 2005;11(3):119–30.PubMedCrossRefGoogle Scholar
  65. Borba EF, Araujo DB, Bonfa E, Shinjo SK. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus. 2013;22(7):744–9.PubMedCrossRefGoogle Scholar
  66. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277–87.PubMedCrossRefGoogle Scholar
  67. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12(2):174–94.PubMedCrossRefGoogle Scholar
  68. Borromeo GL, Tsao CE, Darby IB, Ebeling PR. A review of the clinical implications of bisphosphonates in dentistry. Aust Dent J. 2011;56(1):2–9.PubMedCrossRefGoogle Scholar
  69. Bray GA. Drug treatment of obesity. Rev Endocr Metab Disord. 2001;2(4):403–18.PubMedCrossRefGoogle Scholar
  70. Brennan MT, Valerin MA, Napenas JJ, Lockhart PB. Oral manifestations of patients with lupus erythematosus. Dent Clin N Am. 2005;49(1):127–41, ixPubMedCrossRefGoogle Scholar
  71. Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED, Team DEAR. Long-term safety and effectiveness of mechanical versus biologic aortic valve prostheses in older patients: results from the Society of Thoracic Surgeons adult cardiac surgery National Database. Circulation. 2013;127(16):1647–55.PubMedCrossRefGoogle Scholar
  72. Brown RS, Rhodus NL. Epinephrine and local anesthesia revisited. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(4):401–8.PubMedCrossRefGoogle Scholar
  73. Bucci P, Carile F, Sangianantoni A, D'Angio F, Santarelli A, Lo Muzio L. Oral aphthous ulcers and dental enamel defects in children with coeliac disease.[erratum appears in Acta Paediatr. 2006 Aug;95(8):1023 note: Sangianantoni, Anna [corrected to Sangianantoni, Antonella]]. Acta Paediatr. 2006;95(2):203–7.PubMedCrossRefGoogle Scholar
  74. Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33(4):289–94.PubMedCrossRefGoogle Scholar
  75. Buchner A, Hansen LS. Amalgam pigmentation (amalgam tattoo) of the oral mucosa. A clinicopathologic study of 268 cases. Oral Surg Oral Med Oral Pathol. 1980;49(2):139–47.PubMedCrossRefGoogle Scholar
  76. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.PubMedCrossRefGoogle Scholar
  77. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Socie G, Societe Francaise de Greffe de Moelle et Therapie Cellulaire, Dana Farber Cancer Institute, International Bone Marrow Transplant Registry. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer institute (DFCI), and international bone marrow transplant registry (IBMTR) prospective study. Blood. 2005;106(4):1495–500.PubMedPubMedCentralCrossRefGoogle Scholar
  78. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education Committee of the Council for high blood pressure research. Hypertension. 2008;51(6):1403–19.PubMedCrossRefGoogle Scholar
  79. Calvo-Alen J, Silva-Fernandez L, Ucar-Angulo E, Pego-Reigosa JM, Olive A, Martinez-Fernandez C, Martinez-Taboada V, Luis Marenco J, Loza E, Lopez-Longo J, Gomez-Reino JJ, Galindo-Izquierdo M, Fernandez-Nebro A, Cuadrado MJ, Aguirre-Zamorano MA, Zea-Mendoza A, Rua-Figueroa I. SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin. 2013;9(5):281–96.PubMedCrossRefGoogle Scholar
  80. Carlson GW. The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am. 2000;80(1):261–73, xiiPubMedCrossRefGoogle Scholar
  81. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. the US Tiotropium study group. Chest. 2000;118(5):1294–302.PubMedCrossRefGoogle Scholar
  82. Castano-Rodriguez N, Diaz-Gallo LM, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev. 2008;7(4):322–30.PubMedCrossRefGoogle Scholar
  83. Castini D, Persampieri S, Cazzaniga S, Ferrante G, Centola M, Lucreziotti S, Salerno-Uriarte D, Sponzilli C, Carugo S. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience. Ther Adv Cardiovasc Dis. 2017;11(12):323–31.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, Volta U, Accomando S, Picarelli A, De Vitis I, Pianelli G, Gesuita R, Carle F, Mandolesi A, Bearzi I, Fasano A. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85(1):160–6.PubMedCrossRefGoogle Scholar
  85. Catassi C, Gatti S, Fasano A. The new epidemiology of celiac disease. Journal of Pediatric Gastroenterology & Nutrition. 2014;59(Suppl 1):S7–9.CrossRefGoogle Scholar
  86. Celenligil-Nazliel H, Kansu E, Ebersole JL. Periodontal findings and systemic antibody responses to oral microorganisms in Behcet's disease. J Periodontol. 1999;70(12):1449–56.PubMedCrossRefGoogle Scholar
  87. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European working party on systemic lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–24.CrossRefGoogle Scholar
  88. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernandez-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308.CrossRefGoogle Scholar
  89. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56(6):2092–4.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine J-D, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS 3rd, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, Zone JJ. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–9.PubMedCrossRefGoogle Scholar
  91. Chang NC. Rheumatic diseases in China. J Rheumatol Suppl. 1983;10:41–5.PubMedGoogle Scholar
  92. Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017;96(7):453–61.PubMedGoogle Scholar
  93. Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med. 2000;6(5):424–9.PubMedCrossRefGoogle Scholar
  94. Chehab G, Fischer-Betz R, Schneider M. Changes in mortality and morbidity in systemic lupus erythematosus. Z Rheumatol. 2011;70(6):480–5.PubMedCrossRefGoogle Scholar
  95. Chen Y-H, Xu S-J, Bendahhou S, Wang X-L, Wang Y, Xu W-Y, Jin H-W, Sun H, Su X-Y, Zhuang Q-N, Yang Y-Q, Li Y-B, Liu Y, Xu H-J, Li X-F, Ma N, Mou C-P, Chen Z, Barhanin J, Huang W. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 2003;299(5604):251–4.PubMedCrossRefGoogle Scholar
  96. Chen YC, Lin YH, Chen SH, Chen YC, Chou LF, Chen TJ, Hwang SJ. Epidemiology of adrenal insufficiency: a nationwide study of hospitalizations in Taiwan from 1996 to 2008. J Chin Med Assoc. 2013;76(3):140–5.PubMedCrossRefGoogle Scholar
  97. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147(2):261–5.PubMedCrossRefGoogle Scholar
  98. Cheng J, Brar PS, Lee AR, Green PHR. Body mass index in celiac disease: beneficial effect of a gluten-free diet. J Clin Gastroenterol. 2010;44(4):267–71.PubMedCrossRefGoogle Scholar
  99. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim Y-H, McAnulty JH Jr, Zheng Z-J, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJL. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47.PubMedCrossRefGoogle Scholar
  100. Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Investig Dermatol. 2004;122(5):1091–5.PubMedCrossRefGoogle Scholar
  101. Conan D, Oswswald S, Christine M. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009;139:346–52.Google Scholar
  102. Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107(12):1581–9.PubMedPubMedCentralCrossRefGoogle Scholar
  103. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Practice & Research in Clinical Gastroenterology. 2004;18(3):481–96.CrossRefGoogle Scholar
  104. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004;10(3):178–85.PubMedCrossRefGoogle Scholar
  105. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011;65(5):1064–5.PubMedCrossRefGoogle Scholar
  106. Cruse JM, Lewis RE, Dilioglou S. Fate of immune complexes, glomerulonephritis, and cell-mediated vasculitis in lupus-prone MRL/Mp lpr/lpr mice. Exp Mol Pathol. 2000;69(3):211–22.PubMedCrossRefGoogle Scholar
  107. Cruz-Pamplona M, Jimenez-Soriano Y, Sarrion-Perez MG. Dental considerations in patients with heart disease. J Clin Exp Dent. 2011;3(2):e9–105.Google Scholar
  108. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRefGoogle Scholar
  109. Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME, Travis WD, Travis LB, Horowitz MM, Deeg HJ. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105(10):3802–11.PubMedPubMedCentralCrossRefGoogle Scholar
  110. Curtis EM, Moon RJ, Dennison EM, Harvey NC, Cooper C. Recent advances in the pathogenesis and treatment of osteoporosis. Clin Med (Lond). 2015;15(Suppl 6):s92–6.CrossRefGoogle Scholar
  111. Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006;35(6):472–5.PubMedCrossRefGoogle Scholar
  112. Dalvi SR, Yildirim R, Yazici Y. Behcet's Syndrome. Drugs. 2012;72(17):2223–41.PubMedCrossRefGoogle Scholar
  113. Daniels PR. Peri-procedural management of patients taking oral anticoagulants. BMJ. 2015;351:h2391.PubMedCrossRefGoogle Scholar
  114. Darmstadt GL, Donnenberg AD, Vogelsang GB, Farmer ER, Horn TD. Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol. 1992;99(4):397–402.PubMedCrossRefGoogle Scholar
  115. Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, Akbarian M, Gharibdoost F. High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol. 2003;528:579–84.PubMedCrossRefGoogle Scholar
  116. Davenport S, Chen SY, Miller AS. Pemphigus vulgaris: clinicopathologic review of 33 cases in the oral cavity. International Journal of Periodontics & Restorative Dentistry. 2001;21(1):85–90.Google Scholar
  117. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30(43):10363–70.PubMedCrossRefGoogle Scholar
  118. Davies MJ, Thomas AC. Plaque fissuring – the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53(4):363–73.PubMedPubMedCentralCrossRefGoogle Scholar
  119. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587–96.PubMedCrossRefGoogle Scholar
  120. De Caterina R, Husted S, Wallentin L, Agnelli G, Bachmann F, Baigent C, Jespersen J, Kristensen SD, Montalescot G, Siegbahn A, Verheugt FWA, Weitz J. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007;28(7):880–913.PubMedCrossRefGoogle Scholar
  121. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.PubMedCrossRefGoogle Scholar
  122. Deng Y, Tsao BP. Updates in lupus genetics. Curr Rheumatol Rep. 2017;19(11):68.PubMedCrossRefGoogle Scholar
  123. Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253–62.PubMedCrossRefGoogle Scholar
  124. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308–15.PubMedCrossRefGoogle Scholar
  125. Deviri E, Sareli P, Wisenbaugh T, Cronje SL. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol. 1991;17(3):646–50.PubMedCrossRefGoogle Scholar
  126. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006;92(8):1064–70.PubMedCrossRefGoogle Scholar
  127. Diaz LA, Ratrie H 3rd, Saunders WS, Futamura S, Squiquera HL, Anhalt GJ, Giudice GJ. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Investig. 1990;86(4):1088–94.PubMedPubMedCentralCrossRefGoogle Scholar
  128. Dick SE, Werth VP. Pemphigus: a treatment update. Autoimmunity. 2006;39(7):591–9.PubMedCrossRefGoogle Scholar
  129. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3(7):797–801.PubMedCrossRefGoogle Scholar
  130. Dieterich W, Esslinger B, Schuppan D. Pathomechanisms in celiac disease. International Archives of Allergy & Immunology. 2003;132(2):98–108.CrossRefGoogle Scholar
  131. Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis. 1993;52(11):823–5.PubMedPubMedCentralCrossRefGoogle Scholar
  132. Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc J-M, Morel P, Dubertret L, Bachelez H. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140(1):91–6.PubMedCrossRefGoogle Scholar
  133. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR, Fathman CG, Strober S. Naive and memory T cells induce different types of graft-versus-host disease. J Immunol. 2007;179(10):6547–54.PubMedCrossRefGoogle Scholar
  134. Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet. 1982;2(8312):1356–61.PubMedCrossRefGoogle Scholar
  135. Eisen D. Disorders of pigmentation in the oral cavity. Clin Dermatol. 2000;18(5):579–87.PubMedCrossRefGoogle Scholar
  136. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ, CDC Periodontal Disease Surveillance workgroup: James Beck. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012;91(10):914–20.PubMedCrossRefGoogle Scholar
  137. Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behcet's disease. J Invest Dermatol. 2010;130(8):2136–8.PubMedCrossRefGoogle Scholar
  138. El Fakih R, Jabbour E, Ravandi F, Hassanein M, Anjum F, Ahmed S, Kantarjian H. Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol. 2018;93(2):286–95.PubMedCrossRefGoogle Scholar
  139. Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Dis. 2016;22(1):23–32.PubMedCrossRefGoogle Scholar
  140. Emery DJ, Diaz LA, Fairley JA, Lopez A, Taylor AF, Giudice GJ. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Investig Dermatol. 1995;104(3):323–8.PubMedCrossRefGoogle Scholar
  141. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50(6):974–6.PubMedCrossRefGoogle Scholar
  142. Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol. 2006;86(1):87–9.PubMedGoogle Scholar
  143. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. multiple outcomes of Raloxifene evaluation (MORE) investigators. JAMA. 1999;282(7):637–45.PubMedCrossRefGoogle Scholar
  144. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II euro heart survey programme. Eur Heart J. 2001;22(7):554–72.Google Scholar
  145. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey J-Y, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC).[erratum appears in Eur heart J. 2011 may;32(9):1172]. Eur Heart J. 2010a;31(19):2369–429.CrossRefGoogle Scholar
  146. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey J-Y, Ponikowski P, Rutten FH, E. S. C. C. f. P. Guidelines. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC).[erratum appears in Europace. 2011 Jul;13(7):1058 note: dosage error in article text]. Europace. 2010b;12(10):1360–420.CrossRefGoogle Scholar
  147. Falace DA. Emergency dental care : diagnosis and management of urgent dental problems. Baltimore: Williams & Wilkins; 1995.Google Scholar
  148. Fantasia JE, Damm DD. Oral diagnosis. Mucosal and skin lesions. Pemphigus vulgaris. Gen Dent. 2002;50(1):82, 84.PubMedGoogle Scholar
  149. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008;47(3):292–4.PubMedCrossRefGoogle Scholar
  150. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Behcet's disease using a genome-wide association study. Arthritis Res Ther. 2009;11(3):R66.PubMedPubMedCentralCrossRefGoogle Scholar
  151. Feighner JP, Overo K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 1999;60(12):824–30.PubMedCrossRefGoogle Scholar
  152. Feller L, Masilana A, Khammissa RA, Altini M, Jadwat Y, Lemmer J. Melanin: the biophysiology of oral melanocytes and physiological oral pigmentation. Head Face Med. 2014;10:8.PubMedPubMedCentralCrossRefGoogle Scholar
  153. Femiano F. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis. Minerva Stomatol. 2007;56(4):215–23.PubMedGoogle Scholar
  154. Femiano F, Lanza A, Buonaiuto C, Perillo L, Dell'Ermo A, Cirillo N. Pyostomatitis vegetans: a review of the literature. Medicina Oral, Patologia Oral y Cirugia Bucal. 2009;14(3):E114–7.PubMedGoogle Scholar
  155. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006;43(1):3–10.PubMedCrossRefGoogle Scholar
  156. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, Baethge BA, Vila L, Reveille JD. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–80.PubMedCrossRefGoogle Scholar
  157. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.PubMedCrossRefGoogle Scholar
  158. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2012;113(4):431–41.PubMedCrossRefGoogle Scholar
  159. Fleisher LA. Evaluation of the patient with cardiac disease undergoing noncardiac surgery: an update on the original AHA/ACC guidelines. Int Anesthesiol Clin. 2002;40(2):109–20.PubMedCrossRefGoogle Scholar
  160. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–15.PubMedPubMedCentralCrossRefGoogle Scholar
  161. Foran JM. Do cytogenetics affect the post-remission strategy for older patients with AML in CR1? Best Pract Res Clin Haematol. 2017;30(4):306–11.PubMedCrossRefGoogle Scholar
  162. Fortuna G, Brennan MT. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dent Clin N Am. 2013;57(4):631–55.PubMedCrossRefPubMedCentralGoogle Scholar
  163. Fox PC. Acquired salivary dysfunction. Drugs and radiation. Ann N Y Acad Sci. 1998;842:132–7.PubMedCrossRefGoogle Scholar
  164. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome; findings from the global registry of acute coronary events (GRACE). Eur Heart J. 2002;23(15):1177–89.PubMedCrossRefGoogle Scholar
  165. Franchini M, Mannucci PM. Management of hemophilia in older patients. Drugs Aging. 2017;34(12):881–9.  https://doi.org/10.1007/s40266-017-0500-8.CrossRefGoogle Scholar
  166. Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green WR, Santos GW. Ocular manifestations of graft-vs-host disease. Ophthalmology. 1983;90(1):4–13.PubMedCrossRefGoogle Scholar
  167. Friedlander AH, Birch NJ. Dental conditions in patients with bipolar disorder on long-term lithium maintenance therapy. Spec Care Dentist. 1990;10(5):148–51.PubMedCrossRefGoogle Scholar
  168. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, G. American College of Cardiology/American Heart Association Task Force on Practice, G. European Society of Cardiology Committee for Practice, A. European Heart Rhythm and S. Heart Rhythm. ACC/AHA/ESC 2006 guidelines for the Management of Patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European heart rhythm association and the Heart Rhythm Society.[erratum appears in circulation. 2007 Aug 7;116(6):e138]. Circulation. 2006;114(7):e257–354.PubMedCrossRefGoogle Scholar
  169. Galeazzi M, Sebastiani GD, Morozzi G, Carcassi C, Ferrara GB, Scorza R, Cervera R, de Ramon Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Passiu G, Papasteriades C, Piette JC, Smolen J, Porciello G, Marcolongo R. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore). 2002;81(3):169–78.CrossRefGoogle Scholar
  170. Garcia FVMJ, Pascual-Lopez M, Elices M, Dauden E, Garcia-Diez A, Fraga J. Superficial mucoceles and lichenoid graft versus host disease: report of three cases. Acta Derm Venereol. 2002;82(6):453–5.CrossRefGoogle Scholar
  171. Garcia-Doval I, Mayo E, Nogueira Farina J, Cruces MJ. Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain. Br J Dermatol. 2006;155(4):820–3.PubMedCrossRefGoogle Scholar
  172. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283(23):3082–8.PubMedCrossRefGoogle Scholar
  173. George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–27.PubMedCrossRefGoogle Scholar
  174. Geri G, Wechsler B, Thi Huong du L, Isnard R, Piette JC, Amoura Z, Resche-Rigon M, Cacoub P, Saadoun D. Spectrum of cardiac lesions in Behcet disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012;91(1):25–34.CrossRefGoogle Scholar
  175. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–5.PubMedCrossRefGoogle Scholar
  176. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151(10):5742–50.PubMedGoogle Scholar
  177. Glick M, editor. The oral-systemic health connection: a guide to patient care. Quintessence Publ Co: Hanover Park; 2014.Google Scholar
  178. Glore RJ, Spiteri-Staines K, Paleri V. A patient with dry mouth. Clin Otolaryngol. 2009;34(4):358–63.PubMedCrossRefGoogle Scholar
  179. Goh MSY, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156(5):990–6.PubMedCrossRefGoogle Scholar
  180. Gonzaga CC, Calhoun DA. 2008 American Heart Association statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn. 2008;118(7–8):396–7.PubMedGoogle Scholar
  181. Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E. Topical minocycline for managing symptoms of recurrent aphthous stomatitis. Spec Care Dentist. 2008;28(1):27–31.PubMedCrossRefGoogle Scholar
  182. Graul AI, Sorbera LA, Bozzo J, Serradell N, Revel L, Prous JR. The year's new drugs and biologics – 2006. Drug News Perspect. 2007;20(1):17–44.PubMedGoogle Scholar
  183. Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, Ormerod AD. Annual incidence and mortality of bullous pemphigoid in the Grampian region of north-East Scotland. Br J Dermatol. 2005;153(2):424–7.PubMedCrossRefGoogle Scholar
  184. Gupta SK, Bakhshi S, Chopra A, Kamal VK. Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection. Leuk Lymphoma. 2017; 1–6.  https://doi.org/10.1080/10428194.2017.1408087. [Epub ahead of print]
  185. Gwaltney JM Jr, Park J, Paul RA, Edelman DA, O'Connor RR, Turner RB. Randomized controlled trial of clemastine fumarate for treatment of experimental rhinovirus colds. Clin Infect Dis. 1996;22(4):656–62.PubMedCrossRefGoogle Scholar
  186. Hadjivassiliou M, Duker AP, Sanders DS. Gluten-related neurologic dysfunction. Handb Clin Neurol. 2014;120:607–19.PubMedCrossRefGoogle Scholar
  187. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443–50.PubMedCrossRefGoogle Scholar
  188. Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, Yurdakul S, Numan F, Yazici H. Pulmonary artery aneurysms in Behcet syndrome. Am J Med. 2004;117(11):867–70.PubMedCrossRefGoogle Scholar
  189. Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31(1):5–20.PubMedCrossRefGoogle Scholar
  190. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clinical & Experimental Dermatology. 2000;25(3):236–40.CrossRefGoogle Scholar
  191. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144(4):775–80.PubMedCrossRefGoogle Scholar
  192. Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149(5):926–37.PubMedCrossRefGoogle Scholar
  193. Harper JW, Holleran SF, Ramakrishnan R, Bhagat G, Green PHR. Anemia in celiac disease is multifactorial in etiology. Am J Hematol. 2007;82(11):996–1000.PubMedCrossRefGoogle Scholar
  194. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the euro heart survey of acute coronary syndromes (euro heart survey ACS). Eur Heart J. 2002;23(15):1190–201.PubMedCrossRefGoogle Scholar
  195. Hassona Y, Sawair F, Al-Karadsheh O, Scully C. Prevalence and clinical features of pigmented oral lesions. Int J Dermatol. 2016;55(9):1005–13.PubMedCrossRefGoogle Scholar
  196. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H, Committee EE. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656–62.PubMedCrossRefGoogle Scholar
  197. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm Association. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.PubMedCrossRefGoogle Scholar
  198. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.PubMedCrossRefGoogle Scholar
  199. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford). 2010;49(12):2243–54.CrossRefGoogle Scholar
  200. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25(5):1111–9.PubMedCrossRefGoogle Scholar
  201. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol. 2000;42(3):422–7.PubMedCrossRefGoogle Scholar
  202. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfutze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6(5):366–73.PubMedCrossRefGoogle Scholar
  203. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.PubMedCrossRefGoogle Scholar
  204. Hofmann S, Thoma-Uszynski S, Hunziker T, Bernard P, Koebnick C, Stauber A, Schuler G, Borradori L, Hertl M. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Investig Dermatol. 2002;119(5):1065–73.PubMedCrossRefGoogle Scholar
  205. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405–12.PubMedCrossRefGoogle Scholar
  206. Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, Li F, Zhou Q, Ohno S, Chen R, Kijlstra A, Rosenbaum JT, Yang P. Identification of a susceptibility locus in STAT4 for Behcet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum. 2012;64(12):4104–13.PubMedCrossRefGoogle Scholar
  207. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American College of Cardiology, American Heart Association Task Force on Practice Gudelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and Management of Chronic Heart Failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005a;112(12):e154–235.PubMedCrossRefGoogle Scholar
  208. Hunt SA, American College of Cardiology, American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005b;46(6):e1–82.PubMedCrossRefGoogle Scholar
  209. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(2):175–83.PubMedCrossRefGoogle Scholar
  210. Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC. Oral graft-versus-host disease. Oral Dis. 2008;14(5):396–412.PubMedPubMedCentralCrossRefGoogle Scholar
  211. Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. Clin Endocrinol. 2015;82(6):789–92.CrossRefGoogle Scholar
  212. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behcet's disease. International study Group for Behcet’s disease. Lancet. 1990;335(8697):1078–80.Google Scholar
  213. International Team for the Revision of the International Criteria for Behcet’s Disease. Evaluation of the International Criteria for Behcet’s Disease (ICBD). Clin Exp Rheumatol 2006:24(Suppl 42):S13.Google Scholar
  214. International Team for the Revision of the International Criteria for Behcet’s Disease. The international criteria for Behcet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.CrossRefGoogle Scholar
  215. Interprofessional Education Collaborative. Core competencies for interprofessional collaborative practice: 2016 update. 2016.Google Scholar
  216. Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, Shimizu N, Nishikawa T. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159(4):2010–7.PubMedGoogle Scholar
  217. Iwata Y, Komura K, Kodera M, Usuda T, Yokoyama Y, Hara T, Muroi E, Ogawa F, Takenaka M, Sato S. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol. 2008;144(1):41–8.PubMedCrossRefGoogle Scholar
  218. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005;153(2):448–9.PubMedCrossRefGoogle Scholar
  219. Jacquetin B, Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol. 2001;98(1):97–102.PubMedCrossRefGoogle Scholar
  220. Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, Clementy J. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation. 1997;95(3):572–6.PubMedCrossRefGoogle Scholar
  221. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997;100(12):3019–26.PubMedPubMedCentralCrossRefGoogle Scholar
  222. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.PubMedCrossRefGoogle Scholar
  223. Jamieson NV, Joysey V, Friend PJ, Marcus R, Ramsbottom S, Baglin T, Johnston PS, Williams R, Calne RY. Graft-versus-host disease in solid organ transplantation. Transpl Int. 1991;4(2):67–71.PubMedCrossRefGoogle Scholar
  224. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clinical Gastroenterology & Hepatology. 2013;11(1):43–8.CrossRefGoogle Scholar
  225. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and Management of Heart Failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.PubMedCrossRefGoogle Scholar
  226. Jiang J, Hu Y, Zhang J, Yang J, Mueck W, Kubitza D, Bauer RJ, Meng L, Hu P. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thromb Haemost. 2010;103(1):234–41.PubMedCrossRefGoogle Scholar
  227. Jimenez S, Cervera R, Ingelmo M, Font J. The epidemiology of cutaneous lupus erythematosus. In: Lehmann P, Kuhn A, Ruzicka T, editors. Cutaneous lupus erythematosus. Berlin: Springer; 2004. p. 45e52.Google Scholar
  228. Joly P, Roujeau J-C, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D'Incan M, Plantin P, Bedane C, Young P, Bernard P, Bullous Diseases French Study Group. A comparison of oral and topical cor1ticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.  https://doi.org/10.1056/NEJMoa011592.PubMedCrossRefGoogle Scholar
  229. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60(5):631–7.PubMedCrossRefGoogle Scholar
  230. Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266–8.PubMedCrossRefGoogle Scholar
  231. Kaneko F, Togashi A, Nomura E, Nakamura K. A new diagnostic way for Behcet's disease: skin prick with self-saliva. Genet Res Int. 2014;2014:581468.PubMedPubMedCentralGoogle Scholar
  232. Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, Direskeneli H, Gunaydin Y, Dinc A. The close association between dental and periodontal treatments and oral ulcer course in behcet's disease: a prospective clinical study. J Oral Pathol Med. 2009;38(5):410–5.PubMedCrossRefGoogle Scholar
  233. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–8.PubMedCrossRefGoogle Scholar
  234. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev. 2010;10(1):46–50.PubMedCrossRefGoogle Scholar
  235. Kauzman A, Pavone M, Blanas N, Bradley G. Pigmented lesions of the oral cavity: review, differential diagnosis, and case presentations. J Can Dent Assoc. 2004;70(10):682–3.PubMedGoogle Scholar
  236. Kaviani MJ, Malekzadeh R, Vahedi H, Sotoudeh M, Kamalian N, Amini M, Massarrat S. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial. Eur J Gastroenterol Hepatol. 2001;13(8):915–9.PubMedCrossRefGoogle Scholar
  237. Khalaf MW, Khader R, Cobetto G, Yepes JF, Karounos DG, Miller CS. Risk of adrenal crisis in dental patients: results of a systematic search of the literature. J Am Dent Assoc. 2013;144(2):152–60.PubMedCrossRefGoogle Scholar
  238. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol. 2003;528:575–8.PubMedCrossRefGoogle Scholar
  239. Kim MR, Kim HC, Kim S-C. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients. Dermatology. 2011;223(2):182–8.PubMedCrossRefGoogle Scholar
  240. Kim HJ, Lee KO, Yoo KY, Kim SH, Kim HJ. Maternal low-level somatic mosaicism of Cys155Tyr of F9 in severe hemophilia B. Blood Coagul Fibrinolysis. 2015;26(8):866–8.PubMedCrossRefGoogle Scholar
  241. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev. 2003;1:CD004056.Google Scholar
  242. Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;10:CD002292.Google Scholar
  243. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612–6.  https://doi.org/10.1001/archderm.144.5.612.
  244. Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(2):189–94.PubMedCrossRefGoogle Scholar
  245. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011;9(11):927–47.  https://doi.org/10.1111/j.1610-0387.2011.07809.x.PubMedGoogle Scholar
  246. Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF, Nekolla E, Ljungman P, Jacobsen N, van Weel M, Wick R, Weiss M, Prentice HG. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working Party of the European Cooperative Group for blood and marrow transplantation and the European late effect project group. Ann Intern Med. 1999;131(10):738–44.PubMedCrossRefGoogle Scholar
  247. Kong MF, Jeffcoate W. Eighty-six cases of Addison's disease. Clin Endocrinol. 1994;41(6):757–61.CrossRefGoogle Scholar
  248. Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Peter HH, Kanz L, Stubiger N. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol. 2003;528:521–3.PubMedCrossRefGoogle Scholar
  249. Kuhn A, Ruzicka T. Classification of cutaneous lupus Erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus Erythematosus. Berlin/Heidelberg: Springer; 2005. p. 53–7.CrossRefGoogle Scholar
  250. Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus Erythematosus. Dtsch Arztebl Int. 2015;112(25):423–32.PubMedPubMedCentralGoogle Scholar
  251. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol. 1986;136(4):1231–5.PubMedGoogle Scholar
  252. Lalla E, Lamster IB. Assessment and management of patients with diabetes mellitus in the dental office. Dent Clin N Am. 2012;56(4):819–29.PubMedCrossRefGoogle Scholar
  253. Lalla E, Kunzel C, Burkett S, Cheng B, Lamster IB. Identification of unrecognized diabetes and pre-diabetes in a dental setting. J Dent Res. 2011;90(7):855–60.PubMedCrossRefGoogle Scholar
  254. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S, Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–61.PubMedPubMedCentralCrossRefGoogle Scholar
  255. Lamster IB. Obesity: the oral-systemic connection. In: Glick M, editor. The oral-systemic health connection. Chicago: Quintessence Publishing Co., Inc; 2014.Google Scholar
  256. Lamster IB, Pagan M. Periodontal disease and the metabolic syndrome. Int Dent J. 2017;67(2):67–77.PubMedCrossRefGoogle Scholar
  257. Lamster IB, Lalla E, Borgnakke WS, Taylor GW. The relationship between oral health and diabetes mellitus. J Am Dent Assoc. 2008;139(Suppl):19S–24S.PubMedCrossRefGoogle Scholar
  258. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris – incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.PubMedCrossRefGoogle Scholar
  259. Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol. 2013;19(46):8571–9.PubMedPubMedCentralCrossRefGoogle Scholar
  260. Laplace G, Lafitte S, Labeque J-N, Perron J-M, Baudet E, Deville C, Roques X, Roudaut R. Clinical significance of early thrombosis after prosthetic mitral valve replacement: a postoperative monocentric study of 680 patients. J Am Coll Cardiol. 2004;43(7):1283–90.PubMedCrossRefGoogle Scholar
  261. Laustrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol. 2009;38(2):128–32.PubMedCrossRefGoogle Scholar
  262. Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, Brette M-D, Soued I, Gabison E, Aucouturier F, Letestu R, Laroche L, Bachelez H. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147(7):843–9.PubMedCrossRefGoogle Scholar
  263. Le Tourneau T, Lim V, Inamo J, Miller FA, Mahoney DW, Schaff HV, Enriquez-Sarano M. Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study. Chest. 2009;136(6):1503–13.PubMedPubMedCentralCrossRefGoogle Scholar
  264. Lebwohl B, Ludvigsson JF, Green PHR. Celiac disease and non-celiac gluten sensitivity. BMJ. 2015;351:h4347.PubMedPubMedCentralCrossRefGoogle Scholar
  265. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, Song R, Kang YM, Kang SW, Baek HJ, Kitaichi N, Meguro A, Mizuki N, Namba K, Ishida S, Kim J, Niemczyk E, Lee EY, Song YW, Ohno S, Lee EB. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis. 2013;72(9):1510–6.PubMedCrossRefGoogle Scholar
  266. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Int Rev Immunol. 1997;14(1):21–32.PubMedCrossRefGoogle Scholar
  267. Leite RS, Marlow NM, Fernandes JK. Oral health and type 2 diabetes. Am J Med Sci. 2013;345(4):271–3.PubMedPubMedCentralCrossRefGoogle Scholar
  268. Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111(3):303–10.PubMedCrossRefGoogle Scholar
  269. Liem RI, Chan C, Vu TT, Fornage M, Thompson AA, Liu K, Carnethon MR. Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA. Blood. 2017;129(6):723–8.PubMedPubMedCentralCrossRefGoogle Scholar
  270. Little JW. The impact on dentistry of recent advances in the management of hypertension. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(5):591–9.PubMedCrossRefGoogle Scholar
  271. Little MO. Hypertension: how does management change with aging? Med Clin North Am. 2011;95(3):525–37.PubMedCrossRefGoogle Scholar
  272. Liu W, Shen ZY, Wang LJ, Hu YH, Shen XM, Zhou ZT, Li J. Malignant potential of oral and labial chronic discoid lupus erythematosus: a clinicopathological study of 87 cases. Histopathology. 2011;59(2):292–8.PubMedCrossRefGoogle Scholar
  273. Loesche WJ, Bromberg J, Terpenning MS, Bretz WA, Dominguez BL, Grossman NS, Langmore SE. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. J Am Geriatr Soc. 1995;43(4):401–7.PubMedCrossRefGoogle Scholar
  274. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–17.PubMedCrossRefGoogle Scholar
  275. Loiseau P, Lecleach L, Prost C, Lepage V, Busson M, Bastuji-Garin S, Roujeau JC, Charron D. HLA class II polymorphism contributes to specify desmoglein derived peptides in pemphigus vulgaris and pemphigus foliaceus. J Autoimmun. 2000;15(1):67–73.PubMedCrossRefGoogle Scholar
  276. Long J, Hoban MD, Cooper AR, Kaufman ML, Kuo CY, Campo-Fernandez B, Lumaquin D, Hollis RP, Wang X, Kohn DB, Romero Z. Characterization of gene alterations following editing of the beta-globin gene locus in hematopoietic stem/progenitor cells. Mol Ther. 2018;26(2):468–79.  https://doi.org/10.1016/j.ymthe.2017.11.001. Epub 2017 Nov 9.
  277. Longman LP, Higham SM, Rai K, Edgar WM, Field EA. Salivary gland hypofunction in elderly patients attending a xerostomia clinic. Gerodontology. 1995;12(12):67–72.PubMedCrossRefGoogle Scholar
  278. Lourenco SV, Hussein TP, Bologna SB, Sipahi AM, Nico MMS. Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases. Journal of the European Academy of Dermatology & Venereology. 2010;24(2):204–7.CrossRefGoogle Scholar
  279. Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–6.PubMedPubMedCentralCrossRefGoogle Scholar
  280. Magro CM, Crowson AN. Cutaneous manifestations of Behcet's disease. Int J Dermatol. 1995;34(3):159–65.PubMedCrossRefGoogle Scholar
  281. Mahan CE, Borrego ME, Woersching AL, Federici R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012;108(2):291–302.PubMedPubMedCentralGoogle Scholar
  282. Mancheño Franch A, Jiménez Soriano Y, Sarrión Pérez MG. Dental management of patients with inflammatory bowel disease. J Clin Exp Dent. 2010;2(4):191–5.CrossRefGoogle Scholar
  283. Mangrella M, Motola G, Russo F, Mazzeo F, Giassa T, Falcone G, Rossi F, D'Alessio O, Rossi F. Hospital intensive monitoring of adverse reactions of ACE inhibitors. Minerva Med. 1998;89(4):91–7.PubMedGoogle Scholar
  284. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8.PubMedPubMedCentralCrossRefGoogle Scholar
  285. Mariani P, Mazzilli MC, Margutti G, Lionetti P, Triglione P, Petronzelli F, Ferrante E, Bonamico M. Coeliac disease, enamel defects and HLA typing. Acta Paediatr. 1994;83(12):1272–5.PubMedCrossRefGoogle Scholar
  286. Mars U, Larsson BS. Pheomelanin as a binding site for drugs and chemicals. Pigment Cell Res. 1999;12(4):266–74.PubMedCrossRefGoogle Scholar
  287. Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatol Treat. 2006;17(6):370–6.CrossRefGoogle Scholar
  288. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007;214(4):310–8.PubMedCrossRefGoogle Scholar
  289. Masias C, Wu H, McGookey M, Jay L, Cataland S, Yang S. No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry. Am J Hematol. 2018;93(3):E73–E75. http://doi.org/10.1002/ajh.25002. Epub 2017 Dec 23.PubMedCrossRefGoogle Scholar
  290. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19–28.PubMedCrossRefGoogle Scholar
  291. Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol. 1999;55(2):85–93.PubMedCrossRefGoogle Scholar
  292. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav. 2004;5(Suppl 2):S36–40.PubMedCrossRefGoogle Scholar
  293. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996;55(3):187–9.PubMedPubMedCentralCrossRefGoogle Scholar
  294. Mays JW, Sarmadi M, Moutsopoulos NM. Oral manifestations of systemic autoimmune and inflammatory diseases: diagnosis and clinical management. J Evid Based Dent Pract. 2012;12(3 Suppl):265–82.PubMedCrossRefGoogle Scholar
  295. Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, Guerra R, Orazi BM. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfusion & Apheresis Science. 2003;28(1):13–8.CrossRefGoogle Scholar
  296. McDonald GB, Sullivan KM, Schuffler MD, Shulman HM, Thomas ED. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology. 1981;80(5 pt 1):914–21.PubMedGoogle Scholar
  297. McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 2003;48(8):2100–10.PubMedCrossRefGoogle Scholar
  298. Meleti M, Vescovi P, Mooi WJ, van der Waal I. Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(5):606–16.PubMedCrossRefGoogle Scholar
  299. Mention J-J, Ben Ahmed M, Begue B, Barbe U, Verkarre V, Asnafi V, Colombel J-F, Cugnenc P-H, Ruemmele FM, McIntyre E, Brousse N, Cellier C, Cerf-Bensussan N. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125(3):730–45.PubMedCrossRefGoogle Scholar
  300. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012;73(7):993–1001.PubMedCrossRefGoogle Scholar
  301. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol. 2012;30(1):78–83.PubMedCrossRefGoogle Scholar
  302. Mignogna MD, Lo Muzio L, Mignogna RE, Carbone R, Ruoppo E, Bucci E. Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases. J Oral Pathol Med. 2000;29(4):145–52.PubMedCrossRefGoogle Scholar
  303. Miley DD, Terezhalmy GT. The patient with diabetes mellitus: etiology, epidemiology, principles of medical management, oral disease burden, and principles of dental management. Quintessence Int. 2005;36(10):779–95.PubMedGoogle Scholar
  304. Miller CS, Little JW, Falace DA. Supplemental corticosteroids for dental patients with adrenal insufficiency: reconsideration of the problem. J Am Dent Assoc. 2001;132(11):1570–9; quiz 1596–1577PubMedCrossRefGoogle Scholar
  305. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003;139(6):739–42.PubMedCrossRefGoogle Scholar
  306. Mimouni D, Bar H, Gdalevich M, Katzenelson V, David M. Pemphigus, analysis of 155 patients. Journal of the European Academy of Dermatology & Venereology. 2010;24(8):947–52.CrossRefGoogle Scholar
  307. Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol. 2011;46(2):80–7.PubMedPubMedCentralCrossRefGoogle Scholar
  308. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, Ito N, Kera J, Okada E, Yatsu K, Song YW, Lee EB, Kitaichi N, Namba K, Horie Y, Takeno M, Sugita S, Mochizuki M, Bahram S, Ishigatsubo Y, Inoko H. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMedCrossRefGoogle Scholar
  309. Mollee P, Morton AJ, Irving I, Durrant S. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol. 2001;113(1):217–23.PubMedCrossRefGoogle Scholar
  310. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42. quiz e30PubMedCrossRefGoogle Scholar
  311. Moore PA, Guggenheimer J, Etzel KR, Weyant RJ, Orchard T. Type 1 diabetes mellitus, xerostomia, and salivary flow rates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001a;92(3):281–91.PubMedCrossRefGoogle Scholar
  312. Moore PA, Weyant RJ, Etzel KR, Guggenheimer J, Mongelluzzo MB, Myers DE, Rossie K, Hubar H, Block HM, Orchard T. Type 1 diabetes mellitus and oral health: assessment of coronal and root caries. Community Dent Oral Epidemiol. 2001b;29(3):183–94.PubMedCrossRefGoogle Scholar
  313. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51(5):817–9.PubMedCrossRefGoogle Scholar
  314. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.PubMedCrossRefGoogle Scholar
  315. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839–54.PubMedCrossRefGoogle Scholar
  316. Muller S. Melanin-associated pigmented lesions of the oral mucosa: presentation, differential diagnosis, and treatment. Dermatol Ther. 2010;23(3):220–9.PubMedCrossRefGoogle Scholar
  317. Muzyka BC, Glick M. The hypertensive dental patient. J Am Dent Assoc. 1997;128(8):1109–20.PubMedCrossRefGoogle Scholar
  318. Nachar VR, Perissinotti AJ, Scappaticci GB, Bixby DL, Marini BL. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. Leuk Res. 2017;63:56–61.PubMedCrossRefGoogle Scholar
  319. Napenas JJ, Oost FCD, DeGroot A, Loven B, Hong CHL, Brennan MT, Lockhart PB, van Diermen DE. Review of postoperative bleeding risk in dental patients on antiplatelet therapy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2013;115(4):491–9.PubMedCrossRefGoogle Scholar
  320. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53.PubMedCrossRefGoogle Scholar
  321. Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for Hemophilia. Hematol Oncol Clin North Am. 2017;31(5):853–68.PubMedCrossRefGoogle Scholar
  322. National Hemophilia Foundation. Types of bleeding disorders. 2018. Retrieved 14 Jan 2018. https://stepsforliving.hemophilia.org/.
  323. Nederfors T. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists. Swed Dent J Suppl. 1996;116:1–70.PubMedGoogle Scholar
  324. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.PubMedCrossRefGoogle Scholar
  325. Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. J Can Dent Assoc. 2009;75(1):41.PubMedGoogle Scholar
  326. Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol. 2009;29(3):127–33.PubMedCrossRefGoogle Scholar
  327. Nico MM, Vilela MA, Rivitti EA, Lourenco SV. Oral lesions in lupus erythematosus: correlation with cutaneous lesions. Eur J Dermatol. 2008;18(4):376–81.PubMedGoogle Scholar
  328. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ, European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the euro heart survey on atrial fibrillation. Eur Heart J. 2005;26(22):2422–34.PubMedCrossRefGoogle Scholar
  329. Nishikawa T, Hashimoto T, Shimizu H, Ebihara T, Amagai M. Pemphigus: from immunofluorescence to molecular biology. J Dermatol Sci. 1996;12(1):1–9.PubMedCrossRefGoogle Scholar
  330. Nishimura RA, Otto C. 2014 ACC/AHA valve guidelines: earlier intervention for chronic mitral regurgitation. Heart. 2014;100(12):905–7.PubMedCrossRefGoogle Scholar
  331. Oates TW, Huynh-Ba G, Vargas A, Alexander P, Feine J. A critical review of diabetes, glycemic control, and dental implant therapy. Clin Oral Implants Res. 2013;24(2):117–27.PubMedCrossRefGoogle Scholar
  332. Ogunbodede EO, Adamolekun B, Akintomide AO. Oral health and dental treatment needs in Nigerian patients with epilepsy. Epilepsia. 1998;39(6):590–4.PubMedCrossRefGoogle Scholar
  333. Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, Blaszczyk M. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 2007;8(2):85–92.PubMedCrossRefGoogle Scholar
  334. Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus. 2010;19(12):1365–73.PubMedCrossRefGoogle Scholar
  335. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. The platelet ATP and ADP receptors. Curr Pharm Des. 2006;12(7):859–75.PubMedCrossRefGoogle Scholar
  336. Owlia MB, Mostafavi Pour Manshadi SM, Naderi N. Cardiac manifestations of rheumatological conditions: a narrative review. ISRN Rheumatol. 2012;2012:463620.PubMedPubMedCentralGoogle Scholar
  337. Oyama N, Setterfield JF, Powell AM, Sakuma-Oyama Y, Albert S, Bhogal BS, Vaughan RW, Kaneko F, Challacombe SJ, Black MM. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol. 2006;154(1):90–8.PubMedCrossRefGoogle Scholar
  338. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatients in relation to saliva, medication, and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92(6):641–9.PubMedCrossRefGoogle Scholar
  339. Papoutsis NG, Abdel-Naser MB, Altenburg A, Orawa H, Kotter I, Krause L, Pleyer U, Djawari D, Stadler R, Wollina U, Kohl PK, Gollnick HP, Kirch W, Ochsendorf FR, Keitel W, Martus P, Zouboulis CC. Prevalence of Adamantiades-Behcet's disease in Germany and the municipality of berlin: results of a nationwide survey. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S125.PubMedGoogle Scholar
  340. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153(1):222–3.PubMedCrossRefGoogle Scholar
  341. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kroger N, Lanza F, Nagler A, Sureda A, Mohty M. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786–92.PubMedPubMedCentralCrossRefGoogle Scholar
  342. Patel NJ, Deshmukh A, Pant S, Singh V, Patel N, Arora S, Shah N, Chothani A, Savani GT, Mehta K, Parikh V, Rathod A, Badheka AO, Lafferty J, Kowalski M, Mehta JL, Mitrani RD, Viles-Gonzalez JF, Paydak H. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014;129(23):2371–9.PubMedCrossRefGoogle Scholar
  343. Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R, Kikic F, Calistri E, Fili C, Geromin A, Cerno M, Fanin R. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol. 2006;34(3):389–96.PubMedCrossRefGoogle Scholar
  344. Payne AS, Hanakawa Y, Amagai M, Stanley JR. Desmosomes and disease: pemphigus and bullous impetigo. Curr Opin Cell Biol. 2004;16(5):536–43.PubMedCrossRefGoogle Scholar
  345. Perriard J, Jaunin F, Favre B, Budinger L, Hertl M, Saurat JH, Borradori L. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Investig Dermatol. 1999;112(2):141–7.PubMedCrossRefGoogle Scholar
  346. Persson RE, Izutsu KT, Treulove EL, Persson R. Differences in salivary flow rates in elderly subjects using xerostomatic medications. Oral Surg Oral Med Oral Pathol. 1991;72(1):42–6.PubMedCrossRefGoogle Scholar
  347. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, Committee EG. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26(Suppl 5):v139–51.PubMedCrossRefGoogle Scholar
  348. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897–907.PubMedPubMedCentralCrossRefGoogle Scholar
  349. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.PubMedPubMedCentralCrossRefGoogle Scholar
  350. Pettersson S, Lovgren M, Eriksson LE, Moberg C, Svenungsson E, Gunnarsson I, Welin Henriksson E. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol. 2012;41(5):383–90.PubMedCrossRefGoogle Scholar
  351. Pittock S, Drumm B, Fleming P, McDermott M, Imrie C, Flint S, Bourke B. The oral cavity in Crohn's disease. J Pediatr. 2001;138(5):767–71.PubMedCrossRefGoogle Scholar
  352. Pilotte AP et al. Clin J Oncol Nurs. 2011;15:E83–89.Google Scholar
  353. Pohla-Gubo G, Hintner H. Direct and indirect immunofluorescence for the diagnosis of bullous autoimmune diseases. Dermatol Clin. 2011;29(3):365–72, vii.  https://doi.org/10.1016/j.det.2011.03.001.PubMedCrossRefGoogle Scholar
  354. Poire X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, Cornelissen JJ, Volin L, Russell NH, Socie G, Michallet M, Fegueux N, Chevallier P, Brecht A, Hunault-Berger M, Mohty M, Esteve J, Nagler A, Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation benefits for patients >/= 60 years with acute myeloid leukemia and FLT3-ITD; a study from the acute Leukemia working party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Haematologica. 2017.  https://doi.org/10.3324/haematol.2017.178251.
  355. Popescu SM, Scrieciu M, Mercut V. Hypertensive patients and their management in dentistry. 2013. Article ID 410740; 8 pages.Google Scholar
  356. Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, Black MM. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003;149(1):138–45.PubMedCrossRefGoogle Scholar
  357. Prajapati V, Mydlarski PR. Advances in pemphigus therapy. Skin Therapy Lett. 2008;13(3):4–7.PubMedGoogle Scholar
  358. Priovolou CH, Vanderas AP, Papagiannoulis L. A comparative study on the prevalence of enamel defects and dental caries in children and adolescents with and without coeliac disease. Eur J Paediatr Dent. 2004;5(2):102–6.PubMedGoogle Scholar
  359. Prose NS, Abson KG, Scher RK. Disorders of the nails and hair associated with human immunodeficiency virus infection. Int J Dermatol. 1992;31(7):453–7.PubMedCrossRefGoogle Scholar
  360. Provost TT. Nonspecific cutaneous manifestations of systemic lupus Erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus Erythematosus. Berlin/Heidelberg: Springer; 2005. p. 93–106.CrossRefGoogle Scholar
  361. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455–61.PubMedCrossRefGoogle Scholar
  362. Puy CL. The role of saliva i maintaining oral health and as an aid to diagnosis. Med Oral Patol Oral Cir Bucal. 2006;11:E449–55.Google Scholar
  363. Quadrelli SA, Alvarez C, Arce SC, Paz L, Sarano J, Sobrino EM, Manni J. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 2009;18(12):1053–60.PubMedCrossRefGoogle Scholar
  364. Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol. 2010;55(22):2413–26.PubMedCrossRefGoogle Scholar
  365. Raki M, Tollefsen S, Molberg O, Lundin KEA, Sollid LM, Jahnsen FL. A unique dendritic cell subset accumulates in the celiac lesion and efficiently activates gluten-reactive T cells. [erratum appears in gastroenterology. 2007 Feb;132(2):826-7]. Gastroenterology. 2006;131(2):428–38.PubMedCrossRefGoogle Scholar
  366. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92(7):2303–14.PubMedGoogle Scholar
  367. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187–94.PubMedCrossRefGoogle Scholar
  368. Reilly NR, Aguilar K, Hassid BG, Cheng J, Defelice AR, Kazlow P, Bhagat G, Green PH. Celiac disease in normal-weight and overweight children: clinical features and growth outcomes following a gluten-free diet. Journal of Pediatric Gastroenterology & Nutrition. 2011;53(5):528–31.Google Scholar
  369. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gul A. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet. 2010;42(8):698–702.PubMedPubMedCentralCrossRefGoogle Scholar
  370. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, Straaton KV, Alarcon GS. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA study group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 1998;41(7):1161–72.PubMedCrossRefGoogle Scholar
  371. Rich MW. Epidemiology of atrial fibrillation. J Interv Card Electrophysiol. 2009;25(1):3–8.PubMedCrossRefGoogle Scholar
  372. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, Steiner B, Berg E, Miehlke S, Bornhauser M, Schneider T, Zeitz M, Stein H, Thiel E, Duchmann R, Uharek L. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood. 2006;107(4):1717–23.PubMedCrossRefGoogle Scholar
  373. Riley CK, Terezhalmy GT. The patient with hypertension. Quintessence Int. 2001;32(9):671–90.PubMedGoogle Scholar
  374. Rivera C, Torres I, Gonzalez-Arriagada WA. Haemorrhagic bullae in the oral mucosa with gingival bleeding. BMJ. 2017;359:j4476.PubMedCrossRefGoogle Scholar
  375. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–59.PubMedPubMedCentralCrossRefGoogle Scholar
  376. Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2013;116(3):e191–5.PubMedCrossRefGoogle Scholar
  377. Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart. 2007;93(1):137–42.PubMedPubMedCentralCrossRefGoogle Scholar
  378. Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134(4):465–9.PubMedCrossRefGoogle Scholar
  379. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socie G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855–64.PubMedCrossRefGoogle Scholar
  380. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA, American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–76; quiz 677PubMedPubMedCentralCrossRefGoogle Scholar
  381. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next GEneration in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–41.PubMedCrossRefGoogle Scholar
  382. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.PubMedCrossRefGoogle Scholar
  383. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999;341(17):1284–91.PubMedCrossRefGoogle Scholar
  384. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease – native and prosthetic: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):457S–82S.PubMedCrossRefGoogle Scholar
  385. Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DR. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007;109(7):2751–8.PubMedGoogle Scholar
  386. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47(5):785–8.PubMedCrossRefGoogle Scholar
  387. Sanders DS, Hopper AD, Azmy IAF, Rahman N, Hurlstone DP, Leeds JS, George RR, Bhala N. Association of adult celiac disease with surgical abdominal pain: a case-control study in patients referred to secondary care. Ann Surg. 2005;242(2):201–7.PubMedPubMedCentralCrossRefGoogle Scholar
  388. Sankar V, Noujeim M. Oral manifestations of autoimmune and connective tissue disorders. Atlas Oral Maxillofac Surg Clin North Am. 2017;25(2):113–26.PubMedCrossRefGoogle Scholar
  389. Sanli H, Akay BN, Ayyildiz E, Anadolu R, Ilhan O. Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. Transfusion & Apheresis Science. 2010;43(3):353–9.CrossRefGoogle Scholar
  390. Santos-Gallego CG, Picatoste B, Badimon JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep. 2014;16(4):401.PubMedCrossRefGoogle Scholar
  391. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, Yazganoglu KD, Disci R, Erzengin D, Azizlerli G. Vascular involvement in Behcet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006;45(8):919–21.PubMedCrossRefGoogle Scholar
  392. Sarig O, Bercovici S, Zoller L, Goldberg I, Indelman M, Nahum S, Israeli S, Sagiv N, Martinez de Morentin H, Katz O, Baum S, Barzilai A, Trau H, Murrell DF, Bergman R, Hertl M, Rosenberg S, Nothen MM, Skorecki K, Schmidt E, Zillikens D, Darvasi A, Geiger D, Rosset S, Ibrahim SM, Sprecher E. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Investig Dermatol. 2012;132(7):1798–805.PubMedCrossRefGoogle Scholar
  393. Savage NW, Barber MT, Adkins KF. Pigmentary changes in rat oral mucosa following antimalarial therapy. J Oral Pathol. 1986;15(9):468–71.PubMedCrossRefGoogle Scholar
  394. Schifter M, Yeoh SC, Coleman H, Georgiou A. Oral mucosal diseases: the inflammatory dermatoses. Aust Dent J. 2010;55(Suppl 1):23–38.PubMedCrossRefGoogle Scholar
  395. Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clinical & Experimental Dermatology. 2006;31(4):503–8.CrossRefGoogle Scholar
  396. Schmidt E, Dahnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stocker W, Hashimoto T, Brocker E-B, Recke A, Rose C, Zillikens D. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. 2010;19(5):458–63.PubMedCrossRefGoogle Scholar
  397. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Immunology & Allergy Clinics of North America. 2012;32(2):217–32. vCrossRefGoogle Scholar
  398. Schmidt E, Kraensel R, Goebeler M, Sinkgraven R, Brocker EB, Rzany B, Zillikens D. Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases. Cutis. 2005;76(3):205–9.Google Scholar
  399. Sciubba JJ. Autoimmune aspects of pemphigus vulgaris and mucosal pemphigoid. Adv Dent Res. 1996;10(1):52–6.PubMedCrossRefGoogle Scholar
  400. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003;9(4):165–76.PubMedCrossRefGoogle Scholar
  401. Scully C, Felix DH. Oral medicine – update for the dental practitioner: red and pigmented lesions. Br Dent J. 2005;199(10):639–45.PubMedCrossRefGoogle Scholar
  402. Segura-Egea JJ, Castellanos-Cosano L, Machuca G, Lopez-Lopez J, Martin-Gonzalez J, Velasco-Ortega E, Sanchez-Dominguez B, Lopez-Frias FJ. Diabetes mellitus, periapical inflammation and endodontic treatment outcome. Med Oral Patol Oral Cir Bucal. 2012;17(2):e356–61.PubMedCrossRefGoogle Scholar
  403. Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol. 1999;55(8):583–7.PubMedCrossRefGoogle Scholar
  404. Seol CA, Cho YU, Jang S, Park CJ, Lee JH, Lee JH, Lee KH, Seo EJ. Prognostic significance of recurrent additional chromosomal abnormalities in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Genet. 2017;216-217:29–36.PubMedCrossRefGoogle Scholar
  405. Shakeri R, Zamani F, Sotoudehmanesh R, Amiri A, Mohamadnejad M, Davatchi F, Karakani AM, Malekzadeh R, Shahram F. Gluten sensitivity enteropathy in patients with recurrent aphthous stomatitis. BMC Gastroenterol. 2009;9(1):44.PubMedPubMedCentralCrossRefGoogle Scholar
  406. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM, Khosla C. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297(5590):2275–9.PubMedCrossRefGoogle Scholar
  407. Shannon-Lowe C, Rickinson AB, Bell AI. Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732).  https://doi.org/10.1098/rstb.2016.0271.CrossRefGoogle Scholar
  408. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29(5):267–79.PubMedCrossRefGoogle Scholar
  409. Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK. Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study. J Dermatol. 2006;33(8):541–6.PubMedCrossRefGoogle Scholar
  410. Sherman A, Biswas M, Herzog RW. Innovative approaches for immune tolerance to factor VIII in the treatment of Hemophilia a. Front Immunol. 2017;8:1604.PubMedPubMedCentralCrossRefGoogle Scholar
  411. Shetty SR, Bhowmick S, Castelino R, Babu S. Drug induced xerostomia in elderly individuals: an institutional study. Contemp Clin Dent. 2012;3(2):173–5.PubMedPubMedCentralCrossRefGoogle Scholar
  412. Shimada K, Yokozawa T, Atsuta Y, Kohno A, Maruyama F, Yano K, Taji H, Kitaori K, Goto S, Iida H, Morishima Y, Kodera Y, Naoe T, Morishita Y. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Marrow Transplant. 2005;36(2):115–21.PubMedCrossRefGoogle Scholar
  413. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein a immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol. 2008;158(2):382–8.PubMedCrossRefGoogle Scholar
  414. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52.PubMedCrossRefGoogle Scholar
  415. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology. 1988;8(3):463–70.PubMedCrossRefGoogle Scholar
  416. Singh S. Evidence-based treatments for pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid: a systematic review. Indian Journal of Dermatology, Venereology & Leprology. 2011;77(4):456–69.CrossRefGoogle Scholar
  417. Smikle MF, Barton EN, Morgan OS, Deceulaer K. Photosensitivity and antinuclear antibodies in black patients with systemic lupus erythematosus. J Assoc Acad Minor Phys. 1996;7(2):53–5.PubMedGoogle Scholar
  418. Smith RG, Burtner AP. Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist. 1994;14(3):96–102.PubMedCrossRefGoogle Scholar
  419. Sorce M, Arico M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol Ther. 2008;21(Suppl 1):S6–9.PubMedCrossRefGoogle Scholar
  420. Southerland JH, Gill DG, Gangula PR, Halpern LR, Cardona CY, Mouton CP. Dental management in patients with hypertension: challenges and solutions. Clin Cosmet Investig Dent. 2016;8:111–20.PubMedPubMedCentralCrossRefGoogle Scholar
  421. Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ. Seizure control and mortality in epilepsy. Ann Neurol. 1999;46(1):45–50.PubMedCrossRefGoogle Scholar
  422. Spolarich AE. Risk management strategies for reducing oral adverse drug events. J Evid Based Dent Pract. 2014;14(Suppl):87–94 e81.PubMedCrossRefGoogle Scholar
  423. Sprent J, Kishimoto H. The thymus and central tolerance. Philos Trans R Soc Lond Ser B Biol Sci. 2001;356(1409):609–16.CrossRefGoogle Scholar
  424. Stahl NI, Klippel JH, Decker JL. Fever in systemic lupus erythematosus. Am J Med. 1979;67(6):935–40.PubMedCrossRefGoogle Scholar
  425. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555–63.PubMedCrossRefGoogle Scholar
  426. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell. 1981;24(3):897–903.PubMedCrossRefGoogle Scholar
  427. Stassano P, Di Tommaso L, Monaco M, Iorio F, Pepino P, Spampinato N, Vosa C. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol. 2009;54(20):1862–8.PubMedCrossRefGoogle Scholar
  428. Steinhauer T, Bsoul SA, Terezhalmy GT. Risk stratification and dental management of the patient with cardiovascular diseases. Part I: Etiology, epidemiology, and principles of medical management. Quintessence Int. 2005a;36(2):119–37.PubMedGoogle Scholar
  429. Steinhauer T, Bsoul SA, Terezhalmy GT. Risk stratification and dental management of the patient with cardiovascular diseases. Part II: oral disease burden and principles of dental management. Quintessence Int. 2005b;36(3):209–27.PubMedGoogle Scholar
  430. Stewart PM, Corrie J, Seckl JR, Edwards CR, Padfield PL. A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet. 1988;1(8596):1208–10.PubMedCrossRefGoogle Scholar
  431. Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev. 2012;11(3):226–30.PubMedCrossRefGoogle Scholar
  432. Strakosch CR, Gordon RD. Early diagnosis of Addison's disease; pigmentation as sole symptom. Aust NZ J Med. 1978;8(2):189–90.CrossRefGoogle Scholar
  433. Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H. The use of hyperbaric oxygen for the prevention and Management of Osteoradionecrosis of the jaw: a Dana-Farber/Brigham and Women's Cancer Center multidisciplinary guideline. Oncologist. 2017;22(11):1413.PubMedPubMedCentralCrossRefGoogle Scholar
  434. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007;150(4):197–214.PubMedPubMedCentralCrossRefGoogle Scholar
  435. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–7.PubMedCrossRefGoogle Scholar
  436. Tanasiewicz M, Hildebrandt T, Obersztyn I. Xerostomia of various Etiologies: a review of the literature. Adv Clin Exp Med. 2016;25(1):199–206.PubMedCrossRefGoogle Scholar
  437. Tarakji B, Umair A, Prasad D, Alsakran Altamimi M. Diagnosis of oral pigmentations and malignant transformations. Singapore Dent J. 2014;35C:39–46.  https://doi.org/10.1016/j.sdj.2014.03.001.CrossRefGoogle Scholar
  438. Tench CM, McCurdie I, White PD, D'Cruz DP. The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology (Oxford). 2000;39(11):1249–54.CrossRefGoogle Scholar
  439. Thean D, Alberghini M. Anticoagulant therapy and its impact on dental patients: a review. Aust Dent J. 2016;61(2):149–56.PubMedCrossRefGoogle Scholar
  440. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, Lilly Resistant Schizophrenia Study G. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52–63.PubMedCrossRefGoogle Scholar
  441. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–30.PubMedCrossRefGoogle Scholar
  442. Tucci V, Sokari T. The clinical manifestations, diagnosis, and treatment of adrenal emergencies. Emerg Med Clin North Am. 2014;32(2):465–84.PubMedCrossRefGoogle Scholar
  443. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–80.PubMedCrossRefGoogle Scholar
  444. Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diagnosis, monitoring, and treatment of systemic lupus Erythematosus: a systematic review of clinical practice guidelines. Arthritis Care Res (Hoboken). 2015;67(10):1440–52.CrossRefGoogle Scholar
  445. Turner RJ, Sugiya H. Understanding salivary fluid and protein secretion. Oral Dis. 2002;8(1):3–11.PubMedCrossRefGoogle Scholar
  446. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2000;43(6):1058–64.PubMedCrossRefGoogle Scholar
  447. Turpie AGG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost. 2012;108(5):876–86.PubMedCrossRefGoogle Scholar
  448. Union for International Cancer Control. Acute myelogenous leukemia and acute promyelocytic leukemia: 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. 2014.Google Scholar
  449. van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2015;(12):CD011385.  https://doi.org/10.1002/14651858.CD011385.pub2.
  450. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B. Role of bone-modifying agents in metastatic breast Cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol. 2017.  https://doi.org/10.1200/JCO2017754614.
  451. van Veldhuisen DJ, Charlesworth A, Crijns HJ, Lie KI, Hampton JR. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J. 1999;20(9):666–72.PubMedCrossRefGoogle Scholar
  452. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirjak L, Derksen R, Dorner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–67.PubMedCrossRefGoogle Scholar
  453. VanBuecken D, Lord S, Greenbaum CJ. Changing the course of disease in type 1 diabetes. Endotext. 2000. L. J. De Groot, G. Chrousos, K. Dungan et al. South Dartmouth (MA).Google Scholar
  454. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.[erratum appears in chest. 2012 Apr;141(4):1129 note: dosage error in article text]. Chest. 2012;141(2 Suppl):e637S–68S.PubMedPubMedCentralCrossRefGoogle Scholar
  455. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL study group. Obstet Gynecol. 2000;95(5):718–21.PubMedGoogle Scholar
  456. Vilar MJ, Sato EI. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus. 2002;11(8):528–32.PubMedCrossRefGoogle Scholar
  457. Volta U, Caio G, Stanghellini V, De Giorgio R. The changing clinical profile of celiac disease: a 15-year experience (1998–2012) in an Italian referral center. BMC Gastroenterol. 2014;14:194.PubMedPubMedCentralCrossRefGoogle Scholar
  458. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2000;2:CD000059.Google Scholar
  459. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000;27(3):664–70.PubMedGoogle Scholar
  460. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–50.PubMedCrossRefGoogle Scholar
  461. Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HE, Kolb HJ, Hartz AJ, Rimm AA. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med. 1986;104(2):168–75.PubMedCrossRefGoogle Scholar
  462. Weltman NJ, Al-Attar Y, Cheung J, Duncan DPB, Katchky A, Azarpazhooh A, Abrahamyan L. Management of Dental Extractions in patients taking warfarin as anticoagulant treatment: a systematic review. J Can Dent Assoc. 2015;81:f20.PubMedGoogle Scholar
  463. White K, Arlt W. Adrenal crisis in treated Addison's disease: a predictable but under-managed event. Eur J Endocrinol. 2010;162(1):115–20.PubMedCrossRefGoogle Scholar
  464. Wiener RC, Wu B, Crout R, Wiener M, Plassman B, Kao E, McNeil D. Hyposalivation and xerostomia in dentate older adults. J Am Dent Assoc. 2010;141(3):279–84.PubMedPubMedCentralCrossRefGoogle Scholar
  465. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954–68.PubMedCrossRefGoogle Scholar
  466. Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J. 1997;73(859):286–8.PubMedPubMedCentralCrossRefGoogle Scholar
  467. World Health Organization. Worldwide prevalence of anaemia 1993–2005. WHO global database on anemia. 2008, pp 1–40. http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596657/en/.
  468. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. [erratum appears in circulation. 2010;121(12):e260 note: Stafford, Randall [corrected to Roger, Veronique L]], [erratum appears in circulation. 2011 Oct 18;124(16):e425]. Circulation. 2010;121(7):e46–e215.Google Scholar
  469. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres J-P, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016a;133(4):447–54.CrossRefGoogle Scholar
  470. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016b;133(4):e38–360.CrossRefGoogle Scholar
  471. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583–94.PubMedPubMedCentralCrossRefGoogle Scholar
  472. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood. 2005;105(11):4191–9.PubMedPubMedCentralCrossRefGoogle Scholar
  473. Yagiela JA, Haymore TL. Management of the hypertensive dental patient. J Calif Dent Assoc. 2007;35(1):51–9.PubMedGoogle Scholar
  474. Yano C, Ishiji T, Kamide R, Niimura M. A case of pemphigus vulgaris successfully treated with single filtration plasmapheresis: a correlation of clinical disease activity with serum antibody levels. J Dermatol. 2000;27(6):380–5.PubMedCrossRefGoogle Scholar
  475. Yazici Y, Moses N. Clinical manifestations and ethnic background of patients with Behcet's syndrome in a US cohort. Arthritis Rheum. 2007;56:S502.Google Scholar
  476. Yurdakul S, Yazici H, Tuzun Y, Pazarli H, Yalcin B, Altac M, Ozyazgan Y, Tuzuner N, Muftuoglu A. The arthritis of Behcet's disease: a prospective study. Ann Rheum Dis. 1983;42(5):505–15.PubMedPubMedCentralCrossRefGoogle Scholar
  477. Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum. 2001;44(11):2686–92.PubMedCrossRefGoogle Scholar
  478. Zandman-Goddard G, Solomon M, Rosman Z, Peeva E, Shoenfeld Y. Environment and lupus-related diseases. Lupus. 2012;21(3):241–50.PubMedCrossRefGoogle Scholar
  479. Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91–9.PubMedPubMedCentralCrossRefGoogle Scholar
  480. Zhou WJ, Yang CD. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus. 2009;18(9):807–12.PubMedCrossRefGoogle Scholar
  481. Zhu H, Chen Y, Zhou Y, Wang Y, Zheng J, Pan M. Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris. J Clin Immunol. 2012;32(1):114–23.PubMedCrossRefGoogle Scholar
  482. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903–11.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sue-Ching Yeoh
    • 1
    • 2
  • Hong Hua
    • 3
  • Juan Fernando Yepes
    • 4
  • Douglas E. Peterson
    • 5
  1. 1.Sydney Oral MedicineBaulkham HillsAustralia
  2. 2.Chris O’Brien LifehouseCamperdownAustralia
  3. 3.Department of Oral MedicinePeking University, School of StomatologyBeijingChina
  4. 4.Department of Pediatric DentistryJames Whitcomb Riley Hospital for Children, Indiana University School of DentistryIndianapolisUSA
  5. 5.Department of Oral Health & Diagnostic Sciences, School of Dental MedicineNeag Comprehensive Cancer Center, UConn HealthFarmingtonUSA

Section editors and affiliations

  • Camile S. Farah
    • 1
  1. 1.UWA Dental SchoolUniversity of Western AustraliaPerthAustralia

Personalised recommendations